Seasonal Influenza Prophylactics Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Seasonal Influenza Prophylactics Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Influenza Prophylactics therapeutics.

Across the 16 major markets, there were over 540 million individuals vaccinated against influenza in 2022.

Globally, a high number of vaccines are approved and marketed for the prevention of influenza; AstraZeneca, Sanofi, and GSK are the top key players in this space.

R&D activity within the influenza prophylactics space is highly active, with 18 products in late-stage development across the 16 major markets.

Moderna currently dominates clinical trial development in influenza, with the US emerging as the key country for conducting trials in influenza.

Deals involving partnerships are the most common type of deals in the US and Europe among companies involved in developing influenza assets.

One regulatory filing/commercial launch is expected in the US during the next 18 months, for Novavax’s NanoFlu.

Scope

GlobalData’s Seasonal Influenza Prophylactics Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Influenza Prophylactics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Influenza Prophylactics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.


  • Report Scope
  • Key Findings
  • Disease Overview
  • Epidemiology Overview
    • Epidemiology Overview: Seasonal Influenza Vaccination Coverage in 2022 and 2027
      • Table Epidemiology Overview: Seasonal Influenza Vaccination Coverage in 2022 and 2027
  • Treatment Overview
    • Vaccination Recommendation
  • Marketed Vaccines Assessment
    • Marketed Vaccines - Leading Marketed Vaccines in Influenza
    • Marketed Vaccines - Overview by Target
    • Marketed Vaccines - Overview by Molecule Type
    • Marketed Vaccines - Overview by Route of Administration
    • Marketed Drug Profile: Sanofi's Efluelda
    • Marketed Drug Profile: CSL's Afluria Quad/Afluria Tetra
    • Marketed Drug Profile: Sanofi's Vaxigrip
    • Marketed Drug Profile: Abbott's Influvac Tetra
    • Marketed Drug Profile: CSL's Flucelvax
    • Marketed Drug Profile: AstraZeneca's Fluenz Tetra
    • Marketed Drug Profile: CSL's Afluria Quad/Afluria Tetra
    • Marketed Drug Profile: Sanofi's Flublok Quadrivalent/Supemtek
    • Marketed Drug Profile: Sanofi's Efluelda
  • Pricing and Reimbursement Assessment
    • Marketed Drugs - Average Therapy Cost for Influenza Prophylactics Vaccines
    • Marketed Drugs - Average Cost of Therapy
    • Marketed Drugs - Time to Pricing for Flaud tetra
    • Marketed Drugs - Time to Pricing and Reimbursement for Vaxigrip tetra
    • Marketed Drugs - Time to Pricing and Reimbursement for Flucelvax tetra
    • Marketed Drugs - Time to Pricing and Reimbursement for Influvac tetra
  • Pipeline Vaccines Assessment
    • Pipeline Vaccines Overview - Late-Stage Pipeline Vaccines in Influenza
    • Pipeline Vaccines - Overview by Development Stage
    • Pipeline Vaccines - Overview by Target
    • Pipeline Vaccines - Overview by Route of Administration
    • Pipeline Vaccines - Vaccine-Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) in Influenza Virus Infection
    • Pipeline Vaccines - Phase Transition Success Rates and Likelihood of Approval in Infectious Disease Therapy Area and in Seasonal Influenza Prophylactics
  • Clinical Trials Assessment
    • Clinical Trials in Influenza Prophylactics - Historical Overview
    • Clinical Trials in Influenza Prophylactics - Overview by Phase
    • Clinical Trials in Influenza Prophylactics - Overview by Status
    • Clinical Trials in Influenza Prophylactics - Overview by Phase for Ongoing and Planned Trials
    • Clinical Trials in Influenza Prophylactics - Trials with a Virtual Component
    • Clinical Trials in Influenza Prophylactics - Overview of Trials by Geography
    • Clinical Trials in Influenza Prophylactics - Single-Country and Multinational Trials by Region
    • Clinical Trials in Influenza Prophylactics - Top 20 Sponsors with Breakdown by Phase
    • Clinical Trials in Influenza Prophylactics - Top 20 Sponsors with Breakdown by Status
    • Clinical Trials in Influenza Prophylactics - Overview by Endpoint Status
    • Clinical Trials in Influenza Prophylactics - Overview by Race and Ethnicity
    • Clinical Trials in Influenza Prophylactics - Enrollment Data
    • Clinical Trials in Influenza Prophylactics - Overview of Sites by Geography
    • Clinical Trials in Influenza Prophylactics - Top 20 Countries for Trial Sites
    • Clinical Trials in Influenza Prophylactics - Top 20 Sites Globally
    • Clinical Trials - Feasibility Analysis: Geography Overview
    • Clinical Trials - Feasibility Analysis: Benchmark Models for Influenza Virus A Vaccine
    • Clinical Trials - Feasibility Analysis: Geography Overview
    • Clinical Trials - Feasibility Analysis: Benchmark Models for Influenza Virus B Vaccine
  • Deals Landscape
    • Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in Influenza by Region
    • Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in Influenza
  • Commercial Assessment
    • Commercial Assessment - Key Market Players in Seasonal Influenza Prophylactics
  • Future Market Catalysts
    • Future Market Catalysts - Upcoming Market Catalysts in Influenza
  • Appendix
    • Methodology
    • Methodology - Sales Forecasts
    • Methodology - Pricing and Reimbursement
    • Methodology - Phase Transition Success Rate and Likelihood of Approval Analysis
    • About the Authors
  • Contact Us
    • Contact Us - A Global Network of Offices

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings